Related Experiment Video
Updated: Aug 6, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A
Nicola Perrotta1, Adriana Coluccia1, Francesca Rossi1
1Policlinico Umberto I Hospital, Sapienza University, Rome, Italy.
Background:
Osimertinib has reshaped the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), but its high cost raises persistent questions about value for money.
Objectives:
To review economic evaluations of osimertinib in EGFR-mutated NSCLC and identify the drivers of cost-effectiveness across first-line, second-line/sequential, and adjuvant settings in North America and Europe.
Methods:
This review was registered with PROSPERO (CRD420251139947) and conducted in accordance with PRISMA 2020. We searched PubMed/MEDLINE, Embase, Web of Science Core Collection, and the Cochrane Library through August 2025 for peer-reviewed economic evaluations comparing osimertinib with chemotherapy or earlier-generation EGFR tyrosine kinase inhibitors from a payer perspective. Reporting quality was appraised with CHEERS 2022. Given heterogeneity in models, pricing, and survival extrapolation, results were synthesized narratively, each incremental cost-effectiveness ratio (ICER) interpreted against its own jurisdiction's willingness-to-pay (WTP) threshold.
Results:
Nine studies published between 2018 and 2024 were included. First-line osimertinib improved outcomes but at ICERs of $151,922-$231,123/QALY (US) and €128,343-€273,895/QALY (Europe), exceeding local thresholds. Second-line T790M-positive estimates were favorable and context-dependent ($159,126/QALY US; £41,705/QALY UK under end-of-life criteria). Adjuvant results were most divergent: cost-effective under cure-fraction assumptions but unfavorable when benefit was modeled as delayed recurrence. Price, overall-survival (OS) extrapolation, sequencing, and local WTP thresholds were dominant.
Conclusions:
Osimertinib confers meaningful clinical benefit, but its value for money is context-specific and often uncertain at current list prices. These conclusions rest on few heterogeneous models and warrant caution; sustainable use will depend on price reductions, patient prioritization, maturation of OS data, and outcome-based reimbursement.
More Related Videos
07:59Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...